Fig. 6: UHRF1 inhibitor UM164 displays anti-leukemia activity in vitro. | Cell Death & Disease

Fig. 6: UHRF1 inhibitor UM164 displays anti-leukemia activity in vitro.

From: UHRF1-mediated epigenetic reprogramming regulates glycolysis to promote progression of B-cell acute lymphoblastic leukemia

Fig. 6

A The flowchart of the compound virtual screening process. B Molecular interaction diagram between UHRF1 protein and UM164 compound. C MST analysis of binding affinity between UHRF1 protein and UM164 compound. D The cell proliferation of B-ALL cell lines treated with UM164. E and F The apoptosis and cell cycle of leukemia cells treated with UM164 were detected using flow cytometry. G The mRNA expression level of HK2, SFRP5, and UHRF1 in B-ALL cell lines treated with UM164. H The box diagram of DNA methylation status. I The protein expression levels of SFRP5. J The expression levels of phosphorylated P38 protein and HK2 protein. K Representative ECAR profiles of Nalm6 and Reh cells following UM164 treatment in the glycolytic rate assay. L The hierarchical heatmap of differential metabolites(up) and the violin plot of differential metabolites(down). N6 Nalm6.

Back to article page